Metraipolis › archive › dc_eab6fc6026bc
SGLT2 Inhibitors in the Management of Cardio-Renal-Metabolic Syndrome: A New Therapeutic Era — Europe PMC PMID:41303740
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41303740
- DOI
- 10.3390/medicina61111903
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-09T02:35:42.824Z
- SHA-256 of the archived text
75cdd9f503fcdf6effee2385aa989753c095d0ab55e097bc6a58938c680f0418- Stable URL of this page
https://metraipolis.com/documento/dc_eab6fc6026bc
How to cite
SGLT2 Inhibitors in the Management of Cardio-Renal-Metabolic Syndrome: A New Therapeutic Era — Europe PMC PMID:41303740 — Europe PMC (en), https://europepmc.org/article/MED/41303740 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_eab6fc6026bc (Metraipolis archive dc_eab6fc6026bc, sha256 75cdd9f503fcdf6effee2385aa989753c095d0ab55e097bc6a58938c680f0418)
BibTeX
@misc{dceab6fc6026bc,
title = {SGLT2 Inhibitors in the Management of Cardio-Renal-Metabolic Syndrome: A New Therapeutic Era — Europe PMC PMID:41303740},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41303740},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_eab6fc6026bc; sha256 75cdd9f503fcdf6effee2385aa989753c095d0ab55e097bc6a58938c680f0418},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41303740. Agents can read the archived copy with the MCP tool read_document.